ECO ANIMAL HEALTH GROUP PLC

Regulatory Filings • Nov 27, 2023

National Storage Mechanism | Additional information

RNS Number : 7512U

Eco Animal Health Group PLC

27 November 2023

ECO Animal Health Group plc

(''ECO" or the "Group") (AIM: EAH)

Investor Presentation covering Interim Results

ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to announce that David Hallas, CEO, and Christopher Wilks, CFO, will be conducting a live presentation covering the Group's interim results for the period ended 30 September 2023.

The online presentation will take place on Wednesday 29 November at 3.00pm UK time. This event is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at the end of it.

To register for the event, please click here

A video recording of the presentation will be available shortly afterwards here

Contacts:

ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO)	020 8447 8899
IFC Advisory Graham Herring Zach Cohen	020 3934 6630
Equity Development Hannah Crowe Matt Evans	020 7065 2692

About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUBAKRONUAURA